Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026
Company Drug

AstraZeneca’s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis

Fineline Cube Jan 26, 2026

AstraZeneca plc (AZ, NASDAQ: AZN) announced that China’s National Medical Products Administration (NMPA) has approved Soliris...

Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026

Merck & Co. Inc. (MSD, NYSE: MRK) has reportedly ended acquisition talks with Revolution Medicines after the...

Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Fineline Cube Jan 26, 2026

Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China‑based joint venture established by AstraZeneca (AZ, NASDAQ: AZN)...

Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Fineline Cube Jan 26, 2026

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study

Fineline Cube Jan 26, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that China’s National Medical Products...

Company Drug

Eisai/Biogen’s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer’s Dosing

Fineline Cube Jan 26, 2026

Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug...

Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026

Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company...

Company Drug

Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer

Fineline Cube Jan 23, 2026

Daiichi Sankyo (TYO: 4568) announced that Raludotatug Deruxtecan (R‑DXd, DS‑6000a), a first‑in‑class CDH6‑targeted antibody‑drug conjugate (ADC),...

Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Fineline Cube Jan 23, 2026

Novo Nordisk (NYSE: NVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their...

Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Fineline Cube Jan 23, 2026

Sisram Medical Ltd (HKG: 1696), an Israel‑based beauty and wellness group and part of Fosun...

Company Deals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

Fineline Cube Jan 23, 2026

Becton, Dickinson and Co. (BD) and Swiss injection system developer Ypsomed announced an expanded collaboration...

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced the extension of...

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that SHR‑7877 has received National Medical Products...

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026

PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immune‑inflammatory disease specialist founded in 2016, has filed for...

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Fineline Cube Jan 23, 2026

Johnson & Johnson (J&J, NYSE: JNJ) reported fourth‑quarter revenue of $24.6 billion, up 9.1% year‑on‑year (YOY), bringing...

Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026

AbbVie Inc. (NYSE: ABBV) announced that China’s National Medical Products Administration (NMPA) has approved Risankizumab (SKYRIZI)...

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026

Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced a strategic cooperation agreement with Delim Cosmetics...

Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026

TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative...

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026

China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial...

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026

Matwings Technology, a pioneer in AI‑driven protein engineering, announced a strategic biopharmaceutical pipeline collaboration with...

Posts pagination

1 … 8 9 10 … 621

Recent updates

  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
  • Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
  • Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
  • Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
  • Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.